Dark

Check out our Dark Pool Levels

FOLD
Amicus Therapeutics, Inc
stock NASDAQ

Inactive

Apr 24, 2026

14.49USD+0.207%(+0.03)5,285,334

Pre-market

0.00USD-100.000%(-14.46)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 14, 2022

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 14, 2022 Benzinga

07:29AM EST 10 Biggest Price Target Changes For Friday Benzinga

05:05AM EST SVB Leerink Upgrades Amicus Therapeutics to Outperform, Raises Price Target to $16 Benzinga

Jan 13, 2022

11:45AM EST Cantor Fitzgerald Maintains Overweight on Amicus Therapeutics, Lowers Price Target to $15 Benzinga

Jan 10, 2022

02:31PM EST Mid-Afternoon Market Update: Dow Tumbles 250 Points; Zynga Shares Spike Higher Benzinga

12:26PM EST Mid-Day Market Update: Nasdaq Dips 300 Points; Apria Shares Surge Benzinga

07:39AM EST Amicus Therapeutics Sees FY21 Galafold Sales ~$306M Benzinga

07:00AM EST Full-Year 2021 Galafold Revenue of ~$306M, Representing 17% YoY Growth GlobeNewswire Inc

Jan 5, 2022

07:00AM EST Amicus Therapeutics (Nasdaq: FOLD) today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually on Wednesday, January 12, 2022 at 3:45 p.m. E.T. GlobeNewswire Inc

Dec 3, 2021

07:01AM EST Amicus Therapeutics reports European Medicines Agency Validates Co.'s Marketing Authorization Applications For AT-GAA For Treatment Of Pompe Disease Benzinga

07:00AM EST European Medicines Agency Validates Amicus Therapeutics Marketing GlobeNewswire Inc

Nov 24, 2021

07:00AM EST Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Virtual Conference on Wednesday, December 1, 2021 at 8:50 a.m. E.T. GlobeNewswire Inc

Nov 22, 2021

07:08AM EST Amicus Therapeutics Announces Presentations At The 14th International Congress Of Inborn Errors Of Metabolism Benzinga

07:00AM EST Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters for presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) being held virtually and in Sydney, Australia, November 21-23, 2021. GlobeNewswire Inc

Nov 18, 2021

07:00AM EST Peer Reviewed Results from PROPEL Show Treatment with AT-GAA Provided Clinically Meaningful Improvements Over Standard of Care, including ERT Experienced Patients with High Unmet Need GlobeNewswire Inc

Nov 15, 2021

11:20AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021 Benzinga

10:56AM EST Stifel Upgrades Amicus Therapeutics to Buy, Raises Price Target to $16 Benzinga

Nov 11, 2021

07:00AM EST Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 8:00 a.m. E.T. GlobeNewswire Inc

Nov 9, 2021

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:31AM EST Amicus Therapeutics Q3 EPS $(0.19) Misses $(0.18) Estimate, Sales $79.50M Miss $80.11M Estimate Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

07:00AM EST Amicus Therapeutics Announces Third Quarter 2021 Financial Results GlobeNewswire Inc

Nov 3, 2021

07:00AM EDT Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 9, 2021 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2021. GlobeNewswire Inc

Sep 30, 2021

11:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021 Benzinga

05:05AM EDT JP Morgan Upgrades Amicus Therapeutics to Overweight, Announces $16 Price Target Benzinga

04:33AM EDT SVB Leerink Maintains Market Perform on Amicus Therapeutics, Lowers Price Target to $12 Benzinga

Sep 29, 2021

11:55AM EDT Amicus Therapeutics shares were trading higher after the company announced the FDA accepted filings for its AT-GAA for the treatment of Pompe disease. Benzinga

08:13AM EDT The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga

06:31AM EDT FDA Accepts Filings For Amicus' AT-GAA For Treatment Of Pompe Disease Benzinga

06:30AM EDT FDA Sets PDUFA Target Action Date of May 29, 2022 for the New Drug Application andJuly 29, 2022 for the Biologics License Application GlobeNewswire Inc

06:30AM EDT Business Combination of Amicus Gene Therapy Business with ARYA IV to Resultin the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Companywith Expected ~$400M in Initial Funding GlobeNewswire Inc

Sep 20, 2021

07:00AM EDT Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 26th International Annual Congress of the World Muscle Society (WMS) being held virtually, September 20-24, 2021. GlobeNewswire Inc

Sep 3, 2021

07:00AM EDT Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September: GlobeNewswire Inc

Aug 5, 2021

07:44AM EDT Amicus Therapeutics Says On Track To Achieve FY21 Galafold Revenue Of $300M-$315M Benzinga

07:44AM EDT Amicus Therapeutics Q2 EPS $(0.19) Beats $(0.22) Estimate, Galafold Revenue $77.4M, Up 24% YoY Benzinga

07:00AM EDT 2Q21 Total Galafold (migalastat) Revenue of $77.4M, a 24% increase over 2Q20 GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 4, 2021

07:00AM EDT Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 9:00 a.m. E.T. GlobeNewswire Inc

Aug 2, 2021

08:51AM EDT Amicus's Fabry Disease Medicine Gets European Approval For Use In Adolescents Benzinga

07:16AM EDT Amicus Therapeutics Announces European Commission Approval Of Galafold For Adolescents With Fabry Disease Benzinga

07:00AM EDT Amicus Therapeutics Announces European Commission Approval of GlobeNewswire Inc

Jun 23, 2021

10:48AM EDT Amicus Therapeutics Insights: Return On Capital Employed Benzinga

Jun 15, 2021

01:55PM EDT Amicus Therapeutics Granted U.S. Patent Titled 'Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones' Benzinga

Jun 14, 2021

07:26AM EDT Amicus Therapeutics Appoints Eiry Roberts To Its Board RTTNews

07:00AM EDT Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of GlobeNewswire Inc

Jun 8, 2021

07:07AM EDT Amicus Therapeutics Announces United Kingdom's MHRA Grants Early Access To AT-GAA Benzinga

07:00AM EDT Permits All Eligible Individuals with Late-Onset Pompe Disease Access to AT-GAA Prior to Marketing Authorization in the UK GlobeNewswire Inc

Jun 7, 2021

10:01AM EDT Looking Into Amicus Therapeutics's Return On Capital Employed Benzinga

May 28, 2021

07:05AM EDT Amicus Therapeutics To Present At Goldman Sachs 42nd Annual Global Healthcare Conference Benzinga

07:00AM EDT Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference, being held virtually on Wednesday, June 9, 2021 at 5:30 p.m. E.T. GlobeNewswire Inc

May 27, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 27, 2021 Benzinga

06:18AM EDT Needham Initiates Coverage On Amicus Therapeutics with Hold Rating Benzinga

May 26, 2021

07:33AM EDT The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing Benzinga

May 25, 2021

07:53AM EDT The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal Benzinga

May 21, 2021

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021 Benzinga

07:00AM EDT Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 16th International Congress on Neuromuscular Diseases(ICNMD) being held virtually, May 21-22 and 28-29, 2021. GlobeNewswire Inc

06:40AM EDT UBS Initiates Coverage On Amicus Therapeutics with Buy Rating, Announces Price Target of $16 Benzinga

May 10, 2021

08:01AM EDT Recap: Amicus Therapeutics Q1 Earnings Benzinga

07:19AM EDT Amicus Therapeutics Sees FY21 Revs $300M-$315M Vs $312.64M Est Benzinga

07:18AM EDT Amicus Therapeutics Q1 EPS $(0.25) Misses $(0.24) Estimate, Sales $66.40M Miss $71.65M Estimate Benzinga

07:00AM EDT Galafold (migalastat) PerformanceReflects Continued Strong Adoption in All Key Global Regions; On-Track to Achieve Revenue Guidance of $300M-$315M GlobeNewswire Inc

04:09AM EDT Earnings Scheduled For May 10, 2021 Benzinga

May 7, 2021

07:00AM EDT Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in May: GlobeNewswire Inc

May 6, 2021

07:00AM EDT Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme GlobeNewswire Inc

May 5, 2021

07:28AM EDT Amicus Therapeutics Announces Upcoming Presentations At American Society Of Gene & Cell Therapy 24th Annual Meeting May 11 Benzinga

07:00AM EDT Amicus Therapeutics Announces Upcoming Presentations at the GlobeNewswire Inc

May 3, 2021

08:30AM EDT Amicus Therapeutics Concludes Pre-BLA Meeting With FDA For AT-GAA In Pompe Disease Benzinga

07:04AM EDT Amicus Therapeutics Completes Pre-Biologics License Application Meeting with the FDA for AT-GAA for the Treatment of Pompe Disease, Intends to Complete Rolling BLA Submission for Cipaglucosidase Alfa and Submit a New Drug Application for Miglustat Benzinga

07:00AM EDT Amicus Therapeutics Announces Successful Pre-BLA Meeting with U.S. GlobeNewswire Inc

Apr 28, 2021

07:00AM EDT Amicus Therapeutics Recognized as a Great Place to GlobeNewswire Inc

Apr 26, 2021

07:00AM EDT Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 10, 2021 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2021. GlobeNewswire Inc

Apr 14, 2021

01:20PM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2021 Benzinga

06:54AM EDT Cantor Fitzgerald Upgrades Amicus Therapeutics to Overweight Benzinga

Apr 13, 2021

04:09PM EDT Amicus Therapeutics Shares Higher After Hours As Hearing Cantor Fitzgerald Upgrades To Overweight, Set $17 Price Target Benzinga

Mar 22, 2021

08:30AM EDT 10 Biggest Price Target Changes For Monday Benzinga

06:03AM EDT SVB Leerink Maintains Market Perform on Amicus Therapeutics, Lowers Price Target to $13 Benzinga

Mar 18, 2021

08:16AM EDT The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq Benzinga

Mar 15, 2021

07:00AM EDT Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will be included at the 2021 MDA Virtual Clinical & Scientific Conference to be held March 15-18, 2021. GlobeNewswire Inc

Mar 2, 2021

01:08PM EST Stifel Initiates Coverage On Amicus Therapeutics with Hold Rating, Announces Price Target of $13 Benzinga

Mar 1, 2021

07:24AM EST Amicus Therapeutics: Q4 Earnings Insights Benzinga

07:06AM EST Amicus Therapeutics FY 2020 EPS $(1.07) vs $(1.02) Est, Sales $260.9M vs $259.9M Est Benzinga

07:06AM EST Amicus Therapeutics Sees FY 2021 Galadold Revs $300M-$315M; Sees Non-GAAP Operating Expenses $410M-$420M Benzinga

07:00AM EST 2020 Total Galafold Revenue of $260.9M;Increased 43 Percent Year-on-Year GlobeNewswire Inc

03:51AM EST Earnings Scheduled For March 1, 2021 Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 26, 2021

10:10AM EST Earnings Preview for Amicus Therapeutics Benzinga

Feb 18, 2021

07:00AM EST Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences: GlobeNewswire Inc

Feb 17, 2021

07:00AM EST Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast onMonday, March 1, 2021 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2020. GlobeNewswire Inc

Feb 12, 2021

11:13AM EST Cantor Fitzgerald Downgrades Amicus Therapeutics to Neutral, Lowers Price Target to $17 Benzinga

10:06AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 12, 2021 Benzinga

06:10AM EST JP Morgan Downgrades Amicus Therapeutics to Neutral, Announces $19 Price Target Benzinga

06:09AM EST SVB Leerink Downgrades Amicus Therapeutics to Market Perform, Lowers Price Target to $15 Benzinga

Feb 11, 2021

04:42PM EST UPDATE: Amicus Reports 'AT-GAA outperformed alglucosidase alfa by 14 meters on the primary endpoint and was not statistically significant for superiority' Benzinga

04:04PM EST Amicus Therapeutics Shares To Resume Trade At 4:30 p.m. EST Benzinga

04:04PM EST Amicus Reports AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study Benzinga

04:01PM EST Rolling BLA submission for AT-GAA planned for completion in Q2 and other global regulatory submissions for approval expected throughout 2021 GlobeNewswire Inc

04:00PM EST Amicus Shares Halted, News Pending Benzinga

Feb 8, 2021

02:31PM EST Amicus Therapeutics Highlights Presentation Of Preclinical Fabry Disease Gene Therapy Data At 17th Annual WORLDSymposium 2021 Benzinga

02:30PM EST Amicus Optimized Transgene Show Greater Substrate Reduction than Wild Type Construct Across All Tissues and Doses GlobeNewswire Inc

02:30PM EST Initial Data Suggest Early Signs of Disease Stabilization in Children with Fatal Neurologic Disease GlobeNewswire Inc

Feb 2, 2021

10:05AM EST Amicus Therapeutics Shares Spike Higher; Traders Circulate Dealreporter Rumor Vertex Look At Co For M&A Benzinga

08:15AM EST Amicus Therapeutics Inc Files For Stock Shelf Of Up To 2.55M Shares Of Common Stock By Selling Stockholders Benzinga

Jan 21, 2021

07:00AM EST Amicus Therapeutics Announces Presentations and Posters at the GlobeNewswire Inc

Jan 11, 2021

07:08AM EST Amicus Therapeutics Sees FY20 Galafold Sales of ~$261M Vs. $259.24M Est. Benzinga

07:00AM EST Amicus Therapeutics Reports Preliminary 2020 Revenue and Provides GlobeNewswire Inc

Jan 5, 2021

07:00AM EST Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference, being held virtually on Tuesday, January 12, 2021 at 8:20 a.m. ET. GlobeNewswire Inc

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 14, 2020

05:13AM EST SVB Leerink Maintains Outperform on Amicus Therapeutics, Raises Price Target to $30 Benzinga

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

Dec 7, 2020

07:00AM EST Amicus Therapeutics Named a Great Place to GlobeNewswire Inc

Dec 2, 2020

07:14AM EST Amicus Therapeutics Appoints Michael Kelly To Its Board RTTNews

07:00AM EST Amicus Therapeutics Appoints Michael A. Kelly to its Board of GlobeNewswire Inc

Dec 1, 2020

08:08AM EST The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga

07:20AM EST Amicus Therapeutics Initiates Rolling BLA Submission To FDA For AT-GAA RTTNews

07:00AM EST Amicus Therapeutics Initiates Rolling Biologic License Application GlobeNewswire Inc

Nov 23, 2020

07:00AM EST Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference being held virtually on Tuesday, December 1, 2020 at 2:15 p.m. E.T. GlobeNewswire Inc

Nov 19, 2020

08:17AM EST The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway Benzinga

Nov 18, 2020

07:30AM EST The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted Benzinga

Nov 17, 2020

09:52AM EST Stocks Trading Near 52-Week Highs Just After Open On Tuesday, Nov. 17, 2020: CAPA, FSRVU, TRTN, ATRA, BEEMW, COOP, NBACU, STKL, KLAC, DLB, PCGU, GNTX, CSV, CCCC, DAC, BHVN, DTP, ACHC, GM, QCOM, FOLD, SNX, GRWG, CHI, CHY, UPWK Benzinga

08:32AM EST The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration Benzinga

Nov 11, 2020

10:52AM EST Berenberg Initiates Coverage On Amicus Therapeutics with Hold Rating, Announces Price Target of $21 Benzinga

07:38AM EST The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap Benzinga

Nov 6, 2020

07:47AM EST The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold Benzinga

05:24AM EST SVB Leerink Maintains Outperform on Amicus Therapeutics, Raises Price Target to $24 Benzinga

Nov 5, 2020

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

07:09AM EST Amicus Therapeutics Sees FY20 Galafold Revenue $250M-$260M Benzinga

07:08AM EST Amicus Therapeutics Q3 EPS $(0.25) Misses $(0.22) Estimate, Sales $67.40M Beat $65.10M Estimate Benzinga

07:00AM EST Galafold 3Q20 Revenue of$67.4 Million, On-Track to Achieve Revenue Guidance of $250M-$260M GlobeNewswire Inc

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

08:59AM EST Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23 Benzinga

07:00AM EST Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Credit Suisse 29th Annual Virtual Healthcare Conference on Monday, November 9, 2020 at 8:00 a.m. ET. GlobeNewswire Inc

Oct 27, 2020

08:25AM EDT The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings Benzinga

Oct 22, 2020

07:52AM EDT The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat Benzinga

07:00AM EDT Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2020. GlobeNewswire Inc

Oct 16, 2020

03:46PM EDT Amicus Therapeutics Option Alert: Nov 20 $18 Calls Sweep (29) near the Ask: 434 @ $1.0 vs 708 OI; Earnings 11/9 Before Open [est] Ref=$17.07 Benzinga

09:50AM EDT Amicus Therapeutics Shares Up 3.5%; Hearing M&A Chatter Involving Vertex Benzinga

Oct 12, 2020

07:01AM EDT Amicus Therapeutics Announces 'Positive' Clinical Data for CLN6 Batten Disease Gene Therapy Benzinga

07:00AM EDT Amicus Therapeutics Announces Additional Positive Interim Clinical GlobeNewswire Inc

Oct 11, 2020

11:35AM EDT Last Week's Notable Insider Buys: Element Solutions, Selecta Biosciences And More Benzinga

Sep 24, 2020

07:27AM EDT Amicus Therapeutics Says EMA Granted Priority Medicines Designation To AT-GTX-501 RTTNews

07:06AM EDT Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene Therapy Benzinga

07:00AM EDT Amicus Therapeutics Receives European Medicines Agency PRIME GlobeNewswire Inc

Sep 3, 2020

07:00AM EDT Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September: GlobeNewswire Inc

Aug 11, 2020

07:26AM EDT Citigroup Maintains Buy on Amicus Therapeutics, Raises Price Target to $20 Benzinga

Aug 10, 2020

09:16AM EDT Amicus Therapeutics Affirms FY2020 Sales Guidance from $250.00M-260.00M to $250.00M-260.00M Benzinga

07:27AM EDT Recap: Amicus Therapeutics Q2 Earnings Benzinga

07:13AM EDT Amicus Therapeutics Q2 EPS $(0.20) Beats $(0.26) Estimate, Sales $62.35M Miss $62.38M Estimate Benzinga

07:00AM EDT Galafold 2Q2020 Revenue of$62.4 Million, On-Track to Achieve 2020 Revenue Guidance of$250M-$260M GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 4, 2020

07:00AM EDT Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020 at 9:00 a.m. E.T. GlobeNewswire Inc

Jul 28, 2020

07:00AM EDT Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2020. GlobeNewswire Inc

Jul 17, 2020

09:49AM EDT Amicus Therapeutics shares are trading higher after the company announced it has secured a $400 million non-dilutive debt financing. Benzinga

07:37AM EDT Amicus Therapeutics Reiterates 2020 Galafold Sales Guidance Of $250-$260M Benzinga

07:36AM EDT Amicus Therapeutics Secures $400M Non-Dilutive Debt Financing Benzinga

07:32AM EDT $400M Debt Facility Provides Path to Profitability Without the Need for Any Future Dilutive Financings GlobeNewswire Inc

Share